Incentives for pharmaceutical innovation available in EU legislative instruments are up for review following the Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States of 17 June 2016.

As a contribution to this review, EPHA hosts Medicines Law & Policy experts to launch a set of recommendations to improve the effectiveness of data exclusivity, the supplementary protection certificate and the orphan drug regulation in Europe. Medicines Law & Policy’s recommendations aim to introduce a better balanced incentive structure in the EU, to ensure new medicines are developed and become available at affordable prices.

10:30-11:00 REGISTRATION

11:00-11:05 WELCOME

Yannis Natsis, European Public Health Alliance (EPHA) - @ynatsis, @EPHA_EU

11:05-11:35 RECOMMENDATIONS TO IMPROVE EU RULES ON DATA EXCLUSIVITY, SUPPLEMENTARY PROTECTION CERTIFICATE AND ORPHAN DRUGS

Ellen ’t Hoen LLM, PhD, Medicines Law & Policy - @elltthoen, @MedsLawPolicy
Pascale Boulet LLM, Medicines Law & Policy - @PascaleBoulet, @MedsLawPolicy

11:35-11:50 GAMING THE SYSTEM TO MAINTAIN EXCESSIVE MEDICINES PRICES: THE NEED FOR LEGAL REMEDIES - case studies from the Netherlands

Wilbert Bannenberg MD MSc(CHDC), Pharmaceutical Accountability Foundation - @PharmAccFound

11:50-12:10 RESPONSES BY THE EUROPEAN COMMISSION (DG GROW, DG SANTE)

12:10-12:30 Q&A

12:30-13:30 NETWORKING LUNCH

#healthfirst

The European Public Health Alliance (EPHA) AISBL has received funding from the European Union, in the framework of the Health Programme. Sole responsibility for the content displayed within this document lies with EPHA and the Executive Agency is not responsible for any use that may be made of the information contained therein.